The use of botulinum toxin therapy for lower-extremity spasticity in children with cerebral palsy
Authors:
- Beth E. CrownerBCBeth E. Crowner
- Brad A. RacetteBRBrad A. Racette
Open Access
- 1 August 2006
- journal article
- review article
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Neurosurgical Focus
- Vol. 21 (2) , E1-7
Abstract
✓ Hypertonicity is a leading cause of disability for children with cerebral palsy (CP). Botulinum toxin A (BTA) chemically denervates muscle tissue and is commonly used in the management of lower-extremity hypertonicity in children with CP because of its focal effects and wide safety margin. Randomized controlled trials have demonstrated that BTA injections in the ankle flexors, hamstrings, and adductors reduce spasticity and result in improved passive and active range of motion. In other studies, improvements in gait and measurements of functional outcome were found in appropriately selected children who had been injected with BTA. A multidisciplinary treatment approach that includes physical therapists, occupational therapists, orthotists, neurologists, physicians with expertise in performing botulinum toxin injections, orthopedic surgeons, and neurosurgeons is critical to optimize care in children with lower-extremity tone due to CP. In this paper, the authors propose treatment algorithms based on clinical presentation, detailed dosing, and technical information to optimize the treatment of these children. With a multidisciplinary approach, children with lower-extremity hypertonicity due to CP can experience improvements in muscle tone and function.Keywords
This publication has 35 references indexed in Scilit:
- Treatment of adductor spasticity with BTX‐A in children with CP: a randomized, double‐blind, placebo‐controlled studyDevelopmental Medicine & Child Neurology, 2006
- Botulinum Toxin Treatment of Spastic Equinus in Cerebral PalsyAmerican Journal of Physical Medicine & Rehabilitation, 2005
- Botulinum Toxin for Lower Limb Spasticity in Children with Cerebral PalsyAmerican Journal of Physical Medicine & Rehabilitation, 2004
- Measures of muscle and joint performance in the lower limb of children with cerebral palsyDevelopmental Medicine & Child Neurology, 2003
- Functional outcome of botulinum toxin A injections to the lower limbs in cerebral palsyDevelopmental Medicine & Child Neurology, 2002
- There Is No Accounting for AccountabilityPlastic and Reconstructive Surgery, 2002
- Botulinum toxin for the treatment of cervical dystoniaExpert Opinion on Pharmacotherapy, 2001
- Objective measurement of clinical findings in the use of botulinum toxin type A for the management of children with cerebral palsyEuropean Journal of Neurology, 1999
- Retention of cleaved synaptosome-associated protein of 25 kDa (SNAP-25) in neuromuscular junctions: a new hypothesis to explain persistence of botulinum A poisoningCanadian Journal of Physiology and Pharmacology, 1999
- Topical Review: Baclofen in the Treatment of Cerebral PalsyJournal of Child Neurology, 1996